Search - tctmd.com

Displaying 1 - 20 of 58

Sort: Relevancy | Date

Reductions in Plaque, Inflammation Appear to Explain Statin Benefit in HIV

News Conference News AHA 2023

Reductions in Plaque, Inflammation Appear to Explain Statin Benefit in HIV

November 17, 2023

ESPRIT: Intensive BP-Lowering Reduces MACE in Chinese Patients

News Conference News AHA 2023

ESPRIT: Intensive BP-Lowering Reduces MACE in Chinese Patients

November 13, 2023

Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics

News Conference News AHA 2023

Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics

November 11, 2023

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

News Conference News AHA 2023

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

Michael O'Riordan

November 11, 2023

MINT Hints at Benefits of Liberal Transfusions in Acute MI With Anemia

News Conference News AHA 2023

MINT Hints at Benefits of Liberal Transfusions in Acute MI With Anemia

November 11, 2023

New Carotid Stent Systems Associated With Low Stroke Risk

News Conference News VIVA 2023

New Carotid Stent Systems Associated With Low Stroke Risk

November 09, 2023

Coincidental Nonischemic Cardiomyopathy Impacts Prognosis in CAD

News Conference News AHA 2023

Coincidental Nonischemic Cardiomyopathy Impacts Prognosis in CAD

November 09, 2023

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

News Conference News AHA 2023

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

November 07, 2023

Sirolimus- and Paclitaxel-Coated Balloons Well-Matched for In-Stent Restenosis

News Conference News TCT 2023

Sirolimus- and Paclitaxel-Coated Balloons Well-Matched for In-Stent Restenosis

November 02, 2023

PROMISE II: Deep-Vein Arterialization Durable for Amputation-Free Survival in CLTI

News Conference News VIVA 2023

PROMISE II: Deep-Vein Arterialization Durable for Amputation-Free Survival in CLTI

November 01, 2023

Ultrathin Stent Holds Its Own in High-Bleeding-Risk Patients: COMPARE 60/80

News Conference News TCT 2023

Ultrathin Stent Holds Its Own in High-Bleeding-Risk Patients: COMPARE 60/80

Michael O'Riordan

November 01, 2023

BIOSTEMI: Degradable-Polymer, Ultrathin-Strut DES Shows No Late Catch-up at 5 Years

News Conference News TCT 2023

BIOSTEMI: Degradable-Polymer, Ultrathin-Strut DES Shows No Late Catch-up at 5 Years

October 27, 2023

No Mortality Signal for iFR in Real-world Use: SWEDEHEART

News Conference News TCT 2023

No Mortality Signal for iFR in Real-world Use: SWEDEHEART

October 26, 2023

Does Thrombolysis Have a Role in a Primary-PCI World? Experts Hash It Out

News Conference News TCT 2023

Does Thrombolysis Have a Role in a Primary-PCI World? Experts Hash It Out

Michael O'Riordan

October 25, 2023

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

News Conference News TCT 2023

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

October 25, 2023

Surgeons Support Proposed Changes to Left Main CAD Guidelines

News Conference News EACTS 2023

Surgeons Support Proposed Changes to Left Main CAD Guidelines

Michael O'Riordan

October 13, 2023

AUTHEARTVISIT Reignites RCT vs Real-world Data Debate for AV Repair

News Conference News EACTS 2023

AUTHEARTVISIT Reignites RCT vs Real-world Data Debate for AV Repair

Michael O'Riordan

October 09, 2023

Cardiac Surgeons Issue ‘Call to Action’ to Improve CABG Outcomes in Women

News Conference News EACTS 2023

Cardiac Surgeons Issue ‘Call to Action’ to Improve CABG Outcomes in Women

Michael O'Riordan

October 06, 2023

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

News Conference News ESC 2023

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

Michael O'Riordan

September 06, 2023

ESC/EACTS Task Force Recommends Downgrading PCI in Left Main CAD

News Conference News ESC 2023

ESC/EACTS Task Force Recommends Downgrading PCI in Left Main CAD

Michael O'Riordan

September 05, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.